Telomir Pharmaceuticals, Inc. Annual Net Income (Loss) Attributable to Parent in USD from 2022 to 2023

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Telomir Pharmaceuticals, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2022 to 2023.
  • Telomir Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$5.99M, a 250% decline year-over-year.
  • Telomir Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$23M.
  • Telomir Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$13.1M, a 1430% decline from 2022.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$13.1M -$12.2M -1430% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-29
2022 -$854K Jan 1, 2022 Dec 31, 2022 10-K 2024-03-29
* An asterisk sign (*) next to the value indicates that the value is likely invalid.